Research Analysts Set Expectations for RVMD Q3 Earnings

Key Points

• Lifesci Capital has issued a Q3 2025 earnings forecast for Revolution Medicines, predicting a loss of ($1.32) per share, with a price target set at $80.00 and an "Outperform" rating.
• Revolution Medicines missed its previous earnings estimates with a reported loss of ($1.31) per share for the last quarter, further indicating a decline in earnings year-over-year.
• Thirteen equity research analysts have rated Revolution Medicines with a consensus rating of "Buy" and an average target price of $69.92.

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Equities research analysts at Lifesci Capital issued their Q3 2025 earnings per share estimates for shares of Revolution Medicines in a research note issued on Monday, August 18th. Lifesci Capital analyst C. Zhu forecasts that the company will post earnings per share of ($1.32) for the quarter. Lifesci Capital currently has a "Outperform" rating and a $80.00 target price on the stock. The consensus estimate for Revolution Medicines' current full-year earnings is ($3.49) per share. Lifesci Capital also issued estimates for Revolution Medicines' Q4 2025 earnings at ($1.35) EPS, FY2025 earnings at ($5.11) EPS, Q1 2026 earnings at ($1.41) EPS, Q2 2026 earnings at ($1.44) EPS, Q3 2026 earnings at ($1.51) EPS, Q4 2026 earnings at ($1.49) EPS and FY2026 earnings at ($5.93) EPS.

Several other research firms have also commented on RVMD. Needham & Company LLC reduced their price target on Revolution Medicines from $57.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Wedbush reaffirmed an "outperform" rating and set a $73.00 target price (up from $67.00) on shares of Revolution Medicines in a research note on Tuesday, June 24th. Oppenheimer lifted their target price on shares of Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. HC Wainwright restated a "buy" rating and set a $72.00 price target (down previously from $73.00) on shares of Revolution Medicines in a report on Wednesday, May 14th. Finally, Piper Sandler assumed coverage on shares of Revolution Medicines in a research report on Monday. They set an "overweight" rating and a $75.00 price target on the stock. Thirteen research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Revolution Medicines currently has a consensus rating of "Buy" and a consensus target price of $69.92.

Revolution Medicines Price Performance

Shares of NASDAQ RVMD traded up $0.53 during trading on Wednesday, hitting $37.01. The company had a trading volume of 1,091,784 shares, compared to its average volume of 1,900,156. The stock has a fifty day simple moving average of $37.48 and a two-hundred day simple moving average of $38.39. Revolution Medicines has a fifty-two week low of $29.17 and a fifty-two week high of $62.40. The firm has a market capitalization of $6.92 billion, a price-to-earnings ratio of -8.22 and a beta of 1.16. The company has a quick ratio of 11.79, a current ratio of 11.79 and a debt-to-equity ratio of 0.13.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.37). During the same quarter in the previous year, the business posted ($0.81) earnings per share. The firm's revenue for the quarter was up .0% compared to the same quarter last year.

Institutional Investors Weigh In On Revolution Medicines

A number of institutional investors and hedge funds have recently made changes to their positions in RVMD. Wells Fargo & Company MN raised its stake in shares of Revolution Medicines by 51.8% in the 4th quarter. Wells Fargo & Company MN now owns 88,327 shares of the company's stock valued at $3,863,000 after acquiring an additional 30,155 shares during the period. Envestnet Asset Management Inc. increased its stake in Revolution Medicines by 21.7% during the 4th quarter. Envestnet Asset Management Inc. now owns 11,425 shares of the company's stock worth $500,000 after buying an additional 2,041 shares during the period. Russell Investments Group Ltd. increased its stake in Revolution Medicines by 11.4% during the 4th quarter. Russell Investments Group Ltd. now owns 4,243 shares of the company's stock worth $186,000 after buying an additional 434 shares during the period. Cerity Partners LLC purchased a new stake in Revolution Medicines during the 4th quarter worth approximately $250,000. Finally, Raymond James Financial Inc. purchased a new stake in Revolution Medicines during the 4th quarter worth approximately $14,067,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.